Company Overview
Company Type: Public Company
Website: microbix.com
Number of Employees: 100
Ticker: MBX (TSX)
Year Founded: 1988


Business Description
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably test ingredients for immunoassays and quality assessment and proficiency testing controls (QAPs) that support sample collection devices. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to test for pathogens and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. Microbix Biosystems Inc. was founded in 1988 and is based in Mississauga, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
16.6
Market Capitalization
41.1
TEV/Total Revenue
2.1x
EBITDA
(1.3)
Total Enterprise Value
34.3
TEV/EBITDA
NM
EBIT
(2.0)
Cash & ST Invst.
13.4
P/Diluted EPS Before Extra
NM
Net Income
(2.5)
Total Debt
6.6
Price/Tang BV
1.9x
Capital Expenditure
(2.1)
Total Assets
34.3
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023


Estimates Snapshot (Current Fiscal Year End: Sep-30-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.00)
-
(0.02)
0.03
0.02
Revenue (mm)
4.88
-
17.37
27.63
25.07
EBITDA (mm)
0.31
-
(0.61)
6.10
4.42

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
1.97x
TEV/EBITDA
NM

Non-Periodic Estimates

Recommendation
Buy (1.00)
Target Price
0.80
Potential Upside
166.67%


Key Professionals
Name
Title
Groome, Cameron L.
President, CEO & Director
Currie, James S.
Chief Financial Officer
Hughes, Kenneth 
Chief Operating Officer
Luscher, Mark 
Senior Vice President of Scientific Affairs
Lobb, Christopher B.
Compliance Officer, General Counsel & Secretary
Casselli, Philip 
Senior Vice President of Sales, Business Development & Marketing

Key Board Members
Name
Title
Marino, Martin A.
Independent Chairman of the Board
Groome, Cameron L.
President, CEO & Director
Cochran, Mark A.
Independent Director
Embro-Pantalony, Vaughn C.
Independent Director
Blecher, Peter Martin
Independent Director
Renner, Joseph D.
Independent Director
Stewart, Jennifer 
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
265 Watline Avenue | Mississauga, ON | L4Z 1P3 | Canada
Phone: 905 361 8910   Fax: 905 361 8911

Current and Pending Investors
Lumira Ventures

Prior Investors
Bedford Capital Management Inc., Canadian Medical Discoveries Fund Inc., GrowthWorks Canadian Fund Ltd., L.P., GrowthWorks Ltd., Vivo Capital, LLC

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.30
Market Cap (mm)
41.1
Open
 0.30
Shares Out. (mm)
136.9
Previous Close
 0.30
Float %
85.3%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.30/ 0.30
Diluted EPS Excl. Extra Items
(0.02)
52 wk High/Low
 0.51/ 0.28
P/Diluted EPS Before Extra
NM
Volume (mm)
0.04
Avg 3M Dly Vlm (mm)
0.06
Beta 5Y
0.03


 
Delayed Quote** | Last Updated on Oct-06-2023 04:00 PM (GMT-5)
TSX:MBX - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
ImaRx Therapeutics, Inc., Urokinase
As of September 23, 2008, Urokinase of ImaRx Therapeutics, Inc. was acquired by Microbix Biosystems Inc. ImaRx Therapeutics, Inc., Urokinase manufactures drug which is a clot-dissolving agent used in the treatment of acute massive pulmonary embolism. ImaRx Therapeutics, Inc. is located in Tucson, Arizona.

United States and Canada
Pharmaceuticals
-
-
-
Sequent Biotechnologies Inc.
As of September 29, 2005, Sequent Biotechnologies, Inc. was acquired by Microbix Biosystems, Inc. Sequent Biotechnologies, Inc., an animal biotechnology company, develops technology for the dairy, swine, and beef artificial insemination industry. Its technology includes, a separation device that is used for the separation of male producing sperm from female producing sperm using an immunological technique. The company serves producers of dairy, swine, and beef animals. The company is based in Toronto, Canada.

United States and Canada
Health Care Equipment
-
-
-
Crucible International Biotechnologies Corp.
Crucible International Biotechnologies Corp. was founded in 2010 and is based in Canada. The company operates as a subsidiary of Microbix Biosystems Inc.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-28-2022
-
Buyback
Target
Microbix Biosystems Inc. (TSX:MBX)


-
Apr-28-2021
May-19-2021
Public Offering
Target
Microbix Biosystems Inc. (TSX:MBX)


4.13
Apr-28-2021
May-19-2021
Private Placement
Target
Microbix Biosystems Inc. (TSX:MBX)


0.95
Jan-31-2020
Jan-31-2020
Private Placement
Target
Microbix Biosystems Inc. (TSX:MBX)


1.78
Jun-13-2018
Jun-15-2018
Private Placement
Target
Microbix Biosystems Inc. (TSX:MBX)


0.08
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-29-2023
Company Conference Presentations
Microbix Biosystems Inc. Presents at Capital Event Conference - Muskoka, Sep-29-2023
Sep-27-2023
Client Announcements
Microbix Biosystems Inc. Achieves New QAPs Sales Record
Sep-06-2023
Company Conference Presentations
Microbix Biosystems Inc. Presents at Planet MicroCap Showcase: VANCOUVER 2023, Sep-06-2023 10:00 AM
Aug-14-2023
Earnings Calls
Microbix Biosystems Inc., Q3 2023 Earnings Call, Aug 14, 2023
Aug-10-2023
Buyback Tranche Update
Tranche Update on Microbix Biosystems Inc. (TSX:MBX)'s Equity Buyback Plan announced on September 28, 2022.

M&A Advisors
Foley & Lardner LLP


Advisors
Most Recent Auditor
Ernst & Young LLP
M&A Advisors
Foley & Lardner LLP
Private Placement Advisors
Dominick Capital Corporation, J. F. Mackie & Company Ltd., VIII Capital Corp.
Public Offering Advisors
BDO Canada LLP, Boyle & Co. LLP, Ernst & Young LLP (Canada)


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:21 AM
MBX
Microbix Biosystems Inc 2023_10_05
Reports
15
ValuEngine, Inc.

Oct 02, 2023 06:24 AM
MBX
ValuEngine - Toronto Quantitative Stock Report for MBX
Reports
5
GlobalData

Sep 28, 2023 02:15 AM
MBX
MBX
Reports
12
GlobalData

Sep 11, 2023 11:08 PM
MBX
Microbix Biosystems Inc (MBX.TSE) - Financial Analysis Review
Reports
247
S&P Global Compustat

Sep 07, 2023 03:05 AM
MBX
Microbix Biosystems Inc 2023_09_07
Reports
15
MarketLine

Aug 31, 2023 06:01 AM
MBX
Microbix Biosystems Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
58
GlobalData

Aug 25, 2023 03:19 AM
MBX
Microbix Biosystems Inc (MBX.TSE) - Medical Equipment - Deals and Alliances Profile
Reports
28
GlobalData

Aug 23, 2023 06:49 AM
MBX
Microbix Biosystems Inc (MBX.TSE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
38
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jul 27, 2023 06:00 PM
MBX
Rating Update for Microbix Biosystems Inc
EPS Estimates*
3
S&P Global Compustat

Jul 06, 2023 02:44 AM
MBX
Microbix Biosystems Inc 2023_07_06
Reports
15


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Renner, Joseph D.

9,340,037

6.82

2.8

Feb-27-2023


Groome, Cameron L.

2,920,000

2.13

0.9

Feb-27-2023


Blecher, Peter Martin

2,714,474

1.98

0.8

Feb-27-2023


Stratpath Management Inc.

1,566,704

1.14

0.5

Feb-17-2023


Marino, Martin A.

1,366,667

1.00

0.4

Feb-27-2023


Lawrence Decter Investment Counsel, Inc.

1,257,000

0.92

0.4

Dec-31-2022


Next Edge Capital Corp.

910,000

0.66

0.3

Jun-30-2023


Cochran Ph.D., Mark A.

549,277

0.40

0.2

Feb-27-2023


Casselli, Philip 

521,486

0.38

0.2

Feb-27-2023


Luscher Ph.D., Mark 

369,670

0.27

0.1

Feb-24-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Next Edge Capital Corp.
910,000
30,000

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Klimaszewski, Damian 
40,000
(10,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Abbokinase (Future), Antigen, CathClear (Future), Contract Research and Development Services, DxTM, Kinlytic, LumiSort, Microbix 22, Pathogens, PROCEEDx, PROCEEDxFLOQ, PTDx, REDx Cotrols, REDx FLOQ SARS-CoV-2 Swab-forma Products (Future), REDxTMFLOQ SARS-CoV-2 (Future), SARS-CoV-2 Quality Assessment Products, ThromboClear (Future), Viral Transport Medium Products


Upcoming Events
Date/Time
Type
Dec-22-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-29-2023
-
Microbix Biosystems Inc. (TSX:MBX)
SEDAR
News Releases
151 KB
Sep-27-2023
-
Microbix Biosystems Inc. (TSX:MBX)
SEDAR
News Releases
155 KB
Sep-13-2023
-
Microbix Biosystems Inc. (TSX:MBX)
SEDAR
News Releases
50 KB
Aug-10-2023
-
Microbix Biosystems Inc. (TSX:MBX)
SEDAR
News Releases
117 KB
Aug-10-2023
Jun-30-2023
Microbix Biosystems Inc. (TSX:MBX)
SEDAR
Interim Financial Statements
854 KB
Aug-04-2023
-
Microbix Biosystems Inc. (TSX:MBX)
SEDAR
News Releases
54 KB
Jul-25-2023
-
Microbix Biosystems Inc. (TSX:MBX)
SEDAR
News Releases
39 KB
Jul-05-2023
-
Microbix Biosystems Inc. (TSX:MBX)
SEDAR
News Releases
54 KB
Jun-20-2023
-
Microbix Biosystems Inc. (TSX:MBX)
SEDAR
News Releases
55 KB
Jun-13-2023
-
Microbix Biosystems Inc. (TSX:MBX)
SEDAR
News Releases
37 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Klimaszewski, Damian 
Jul-07-2023 - Jul-11-2023
Common Shares
(10,000)
(3,768)
Open Market Disposition
(20.00)
Multiple
-
Jul-07-2023
Common Shares
(1,000)
(386)
Open Market Disposition
-
Exchange Announcement
-
Jul-11-2023
Common Shares
(8,000)
(3,011)
Open Market Disposition
-
Exchange Announcement
-
Jul-11-2023
Common Shares
(1,000)
(371)
Open Market Disposition
-
Exchange Announcement
Klimaszewski, Damian 
May-26-2023
Common Shares
50,000
10,782
Derivative Exercise and Retained Stock
New
Multiple
Groome, Cameron L. (President, CEO & Director)
Feb-21-2023
Common Shares
(47,500)
(17,802)
Other Disposition
(1.60)
Multiple
Groome, Cameron L. (President, CEO & Director)
Feb-21-2023
Common Shares
47,500
17,802
Other Acquisition
1.65
Multiple
Casselli, Philip  (Senior Vice President of Sales, Business Development & Marketing)
Feb-21-2023
Common Shares
100,000
23,297
Derivative Exercise and Retained Stock
23.73
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Marino, Martin A.
Independent Chairman of the Board
905 361 8910
905 361 8911

Groome, Cameron L.
President, CEO & Director
(905) 361-8910
905 361 8911

Cochran, Mark A.
Independent Director
905 361 8910
905 361 8911

Embro-Pantalony, Vaughn C.
Independent Director
905 361 8910
905 361 8911
vaughn.embro-pantalony@microbix.com
Blecher, Peter Martin
Independent Director
905 361 8910
905 361 8911

Renner, Joseph D.
Independent Director
905 361 8910
905 361 8911

Stewart, Jennifer 
Independent Director
905 361 8910
905 361 8911

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Groome, Cameron L.
President, CEO & Director
(905) 361-8910
905 361 8911

Currie, James S.
Chief Financial Officer
(905) 361-8910
905 361 8911
jim.currie@microbix.com
Hughes, Kenneth 
Chief Operating Officer
905 361 8910
905 361 8911

Luscher, Mark 
Senior Vice President of Scientific Affairs
905 361 8910
905 361 8911

Lobb, Christopher B.
Compliance Officer, General Counsel & Secretary
905 361 8910
905 361 8911

Casselli, Philip 
Senior Vice President of Sales, Business Development & Marketing
905 361 8910
905 361 8911
-
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
